At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
First two GMP doses of rese-cel manufactured on the Cell Shuttle(TM) met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET(TM) ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...
Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.
TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...
Plasmid DNA is critical for cell and gene therapies, but scaling high-purity production remains challenging as CDMO partners ...
Wang tells PV Tech Premium that copper offers a ‘a compelling combination’ of traits to replace silver. Image: AIKO. This Premium article, which was one of the most read Premium articles in 2025, has ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s ("Cabaletta Bio" or "Cabaletta") (Nasdaq: CABA) investigational CAR T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results